Orgenesis INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
ORGS
Orgenesis INCOrgenesis Inc. reported its Q3 2024 results, marked by a Nasdaq delisting, the reconsolidation of Octomera, and various strategic transactions.
OTC.Pink
ORGS
Orgenesis INCOrgenesis Inc. reported its financial results for the second quarter of 2024, highlighting a revenue increase but also ongoing challenges with profitability and Nasdaq compliance.
OTC.Pink
ORGS
Orgenesis INC10-Q: Orgenesis Inc. Reports First Quarter 2024 Results Amidst Restructuring and Financial Challenges
Orgenesis Inc. reported its first quarter 2024 results, marked by a net loss, the reconsolidation of Octomera, and ongoing efforts to address financial and listing challenges.
OTC.Pink
ORGS
Orgenesis INCOrgenesis Inc. has amended its Q3 2023 report to correct accounting errors related to revenue recognition, credit losses, and equity investments.
OTC.Pink
ORGS
Orgenesis INCOrgenesis Inc. has amended its Q2 2023 quarterly report to restate financials due to errors in revenue recognition and credit loss accounting.
OTC.Pink
ORGS
Orgenesis INCOrgenesis Inc. has amended its Q1 2023 quarterly report to restate financial statements due to errors in revenue recognition and credit loss accounting.